SION Stock Overview

A clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). More details

SION fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 15.1% per year for the next 3 years

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Sionna Therapeutics, Inc. Competitors

Regulus Therapeutics

NasdaqCM:RGLS

US$544.9m

Cogent Biosciences

NasdaqGS:COGT

US$548.0m

Tyra Biosciences

NasdaqGS:TYRA

US$536.6m

Keros Therapeutics

NasdaqGM:KROS

US$554.4m

Price History & Performance

Summary of share price highs, lows and changes for Sionna Therapeutics
Historical stock prices
Current Share Price	US$12.32
52 Week High	US$25.19
52 Week Low	US$7.26
Beta	0
1 Month Change	56.54%
3 Month Change	-39.64%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.72%

Recent updates

Shareholder Returns

	SION	US Biotechs	US Market
7D	-3.7%	-8.7%	0.3%
1Y	n/a	-15.3%	8.0%

Return vs Industry: Insufficient data to determine how SION performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SION performed against the US Market.

Price Volatility

Is SION's price volatile compared to industry and market?
SION volatility
SION Average Weekly Movement	14.9%
Biotechs Industry Average Movement	11.9%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	4.2%

Stable Share Price: SION's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SION's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	41	Mike Cloonan	www.sionnatx.com

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.

Sionna Therapeutics, Inc. Fundamentals Summary

How do Sionna Therapeutics's earnings and revenue compare to its market cap?
SION fundamental statistics
Market cap	US$543.61m
Earnings (TTM)	-US$61.69m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.8x

P/E Ratio

Is SION overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SION income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$61.69m
Earnings	-US$61.69m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.40
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SION perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 09:54
End of Day Share Price	2025/05/09 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sionna Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Salveen Richter	Goldman Sachs
Yatin Suneja	Guggenheim Securities, LLC
Paul Matteis	Stifel, Equities Research

Sionna Therapeutics NasdaqGM:SION Stock Report